nach oben

Erschienen in:

23.02.2024 | Original Article

Uncertainty Analysis of Time-Integrated Activity Coefficient in Single-Time-Point Dosimetry Using Bayesian Fitting Method

verfasst von: Achmad Faturrahman Jundi, M. Dlorifun Naqiyyun, Bisma Barron Patrianesha, Intan A. S. Mu’minah, Ade Riana, Deni Hardiansyah

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Calculation of the uncertainty of the individual time-integrated activity coefficient (TIACs) is desirable in molecular radiotherapy. However, the calculation of TIAC’s uncertainty in single-time-point (STP) method has never been reported in the literature. This study presents a method based on the Bayesian fitting (BF) to calculate the standard deviation (SD) of individual TIACs in the STP dosimetry.

Methods

Biokinetic data of ¹⁷⁷Lu-DOTATATE in kidneys were obtained from PMID33443063. BF methods with extended objective function, which optimize the fitting using prior knowledge of the function’s parameters, were used. Reference TIACs (rTIACs) were calculated by fitting a mono-exponential function to the all-time-point data. The goodness of fit was checked based on the visual inspection and the coefficient of variations (CV) of the fitted parameters < 0.5. BF with relative (BFr) and absolute-based (BFa) variance methods were used to obtain the calculated TIACs (cTIACs) from the STP dosimetry. Performance of the STP method was obtained by calculating the relative deviation (RD) between cTIACs and rTIACs.

Results

Visual inspection showed a good fit for all patients with CV of fitted parameters less than 50%. The mean ± SD of cTIAC’s %RD were 7.0 ± 25.2 for BFr and 2.6 ± 8.9 for BFa. The range of %CV of the individual cTIAC’s SD for BFr and BFa methods was 36–78% and 22–33%, respectively, while the %CV of the rTIAC SD was 0.8–49%.

Conclusion

We introduce the BF method to calculate the SD of individual TIACs in STP dosimetry. The presented method might be used as an alternative method for uncertainty analysis in STP dosimetry.

Nur mit Berechtigung zugänglich

Lassmann M, Chiesa C, Flux G, Bardiès M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38:192–200.CrossRefPubMed

Glatting G, Bardiès M, Lassmann M. Treatment planning in molecular radiotherapy. Z Med Phys. 2013;23:262–9.CrossRefPubMed

Hardiansyah D, Maass C, Attarwala AA, Müller B, Kletting P, Mottaghy FM, et al. The role of patient-based treatment planning in peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2016;43:871–80.CrossRefPubMed

Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation dosimetry in 177lu-psma-617 therapy using a single posttreatment spect/ct scan: A novel methodology to generate time- and tissue-specific dose factors. J Nucl Med. 2020;61:1030–8.CrossRefPubMedPubMedCentral

Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry. EJNMMI Phys. 2020;7:41.CrossRefPubMedPubMedCentral

Devasia TP, Dewaraja YK, Frey KA, Wong KK, Schipper MJ. A novel time-activity information-sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT/CT after 177Lu-DOTATATE. J Nucl Med. 2021;62:1118–25.CrossRefPubMedPubMedCentral

Hardiansyah D, Riana A, Beer AJ, Glatting G. Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of concept. EJNMMI Phys. 2023;10:1–12.CrossRef

Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177 Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59:75–81.CrossRefPubMed

Ligonnet T, Pistone D, Auditore L, Italiano A, Amato E, Campennì A, et al. Simplified patient-specific renal dosimetry in 177Lu therapy: a proof of concept. Phys Medica. 2021;92:75–85.CrossRef

10.

Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45:2456–74.CrossRefPubMedPubMedCentral

11.

Finocchiaro D, Gear JI, Fioroni F, Flux GD, Murray I, Castellani G, et al. Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. EJNMMI Phys. 2020;7:63.CrossRefPubMedPubMedCentral

12.

Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following 177 Lu-DOTATATE (‘Lutate’) therapy. EJNMMI Phys. 2018;5:33.CrossRefPubMedPubMedCentral

13.

Peters SMB, Hofferber R, Privé BM, de Bakker M, Gotthardt M, Janssen M, et al. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49:1101–12.CrossRefPubMed

14.

Brosch-Lenz J, Delker A, Völter F, Unterrainer LM, Kaiser L, Bartenstein P, et al. Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy. J Nucl Med. 2023;64:767–74.CrossRefPubMedPubMedCentral

15.

Maaß C, Sachs JP, Hardiansyah D, Mottaghy FM, Kletting P, Glatting G. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule. EJNMMI Res. 2016;6:1–9.CrossRef

16.

Hardiansyah D, Guo W, Kletting P, Mottaghy FM, Glatting G. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: a simulation study on the effect of sampling schedule and noise. Med Phys. 2016;43:5145–54.CrossRefPubMed

17.

Kletting P, Kull T, Maaß C, Malik N, Luster M, Beer AJ, et al. Optimized peptide amount and activity for 90Y-labeled DOTATATE therapy. J Nucl Med. 2016;57:503–8.CrossRefPubMed

18.

Kletting P, Maaß C, Reske S, Beer AJ, Glatting G. Physiologically based pharmacokinetic modeling is essential in 90Y-labeled anti-CD66 radioimmunotherapy. PLoS ONE. 2015;10:1–15.CrossRef

19.

Ardenfors O, Nilsson JN, Thor D, Hindorf C. Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy. EJNMMI Phys. 2022;9:44.CrossRefPubMedPubMedCentral

20.

Tran-Gia J, Lassmann M. Characterization of noise and resolution for quantitative 177 Lu SPECT/CT with XSPECT quant. J Nucl Med. 2019;60:50–9.CrossRefPubMed

21.

Mirando D, Dewaraja YK, Cole NM, Nelson AS. In pursuit of fully automated dosimetry: evaluation of an automatic VOI propagation algorithm using contour intensity-based SPECT alignments. Eur J Nucl Med Mol Imaging. 2020;In: Eur. J. Nucl. Med. Mol. Imaging. Springer One New York Plaza, Suite 4600, New York, Ny, United States, pp S236–S236.

22.

Kletting P, Schimmel S, Kestler HA, Hänscheid H, Luster M, Fernández M, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys. 2013;40: 102504.CrossRefPubMed

23.

Bonate PL. Pharmacokinetics pharmacodynamics modeling and simulation, 2nd ed. 2011;Springer, New York.

24.

Barrett PHR, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484–92.CrossRefPubMed

25.

Hardiansyah D, Riana A, Kletting P, Zaid NRR, Eiber M, Pawiro SA, et al. A population-based method to determine the time-integrated activity in molecular radiotherapy. EJNMMI Phys. 2021;8:82.CrossRefPubMedPubMedCentral

26.

Kletting P, Schimmel S, Hänscheid H, Luster M, Fernández M, Nosske D, et al. The NUKDOS software for treatment planning in molecular radiotherapy. Z Med Phys. 2015;25:264–74.CrossRefPubMed

27.

Mahmoudi E, Pirayesh E, Deevband MR, Amoui M, Rad MG, Ghorbani M. Patient-specific dosimetry in radioligand therapy (RLT) for metastatic prostate cancer using 177Lu-DKFZ-PSMA-617. Nucl Med Mol Imaging. 2010;2021(55):237–44.

28.

Hardiansyah D, Riana A, Eiber M, Beer AJ, Glatting G. Population-based model selection for an accurate estimation of time-integrated activity using non-linear mixed-effects modelling. Zeitschrift fuer Medizinische Phys. 2023;1–9. https://doi.org/10.1016/j.zemedi.2023.01.007.

29.

Vegt E, De JM, Wetzels JFM, Masereeuw R, Melis M, Oyen WJG, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049–58.CrossRefPubMed

Titel: Uncertainty Analysis of Time-Integrated Activity Coefficient in Single-Time-Point Dosimetry Using Bayesian Fitting Method
verfasst von: Achmad Faturrahman Jundi
M. Dlorifun Naqiyyun
Bisma Barron Patrianesha
Intan A. S. Mu’minah
Ade Riana
Deni Hardiansyah
Publikationsdatum: 23.02.2024
Verlag: Springer Nature Singapore
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 3/2024
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-024-00851-8

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

Association Between 18F-FDG PET Activity and HER2 Status in Breast Cancer Brain Metastases

Hepatic Superscan in Medullary Thyroid Carcinoma: A Rare Presentation in [18F]FDG PET/CT

Contribution of ChatGPT in Parkinson’s Disease Detection

Recent Updates on Applications of Artificial Intelligence for Nuclear Medicine Professionals: Prostate Cancer and PET/CT

Incidentally Detected Gallbladder Carcinoma: Can F-18 FDG PET/CT Aid in Staging and Prognostication?

First Local Experience of Intra-Cavitary Yttrium-90 Citrate Colloid Irradiation via Ommaya Reservoir for Refractory Cystic Craniopharyngioma: a Case Report